Article Text

Download PDFPDF
How do SSRIs help patients with irritable bowel syndrome?
  1. F Creed
  1. Correspondence to:
    Professor F Creed
    University of Manchester, Rawnsley Building, Manchester Royal Infirmary, Oxford Road, Manchester M13 9 WL, UK; francis.creed{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Selective serotonin reuptake inhibitor antidepressants seem to promote global well being in some patients with irritable bowel syndrome and, possibly, some improvement in abdominal pain and bowel symptoms, but this effect appears to be independent of improved depression

In the randomised controlled trial reported in this issue of Gut, Tack and colleagues1 compared citalopram and placebo in 23 patients with irritable bowel syndrome (IBS) over a six week initial treatment period using a parallel group design (see page 1095). The dose of citalopram was similar to that used in the treatment of depressive disorders but any patients with depressive disorder were excluded from this trial. The results showed that citalopram was superior to placebo in terms of the primary outcome measure—days with abdominal pain—and this improvement was unrelated to change in mood, change in stool pattern, or the effect of intravenous citalopram on rectal distension thresholds.

Overall this was not a good trial. The total number of outcome measures exceeded the number of subjects in the trial. The crossover part of the trial was discounted because symptoms did not return to baseline values after the first treatment period. It is not at all clear how the patients were selected and, therefore, whether the results might be generalised to clinic populations. Strengths of the study however include the high participation rate throughout the trial and the combined diary and questionnaire measurements.

In spite of the weaknesses of the trial design, this report is interesting because of the paucity of randomised placebo controlled trials of selective serotonin reuptake inhibitor (SSRI) antidepressants in IBS.2,3 In one trial of patients who had failed to respond to a high fibre diet, Tabas et al found that a low dose of paroxetine was superior to placebo in terms of overall …

View Full Text

Linked Articles